Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical firm Protherics has enrolled the first patient in a multinational, randomized, Phase IIb study of OncoGel, a novel locally-administered sustained-release formulation of paclitaxel for the treatment of solid tumours.
Subscribe to our email newsletter
The study will evaluate OncoGel administered in combination with pre-operative chemoradiotherapy versus pre-operative chemoradiotherapy alone in 124 patients. The primary endpoint of the study is a blinded assessment of tumor response, overall survival is one of the secondary endpoints. Protherics expects to have preliminary data available from the Phase IIb study in the first half of 2010.
Andrew Heath, CEO of Protherics, said: “Following the encouraging Phase IIa study, we are hopeful that the Phase IIb study will provide further data to support the use of OncoGel as a potential treatment to increase the life expectancy for people with oesophageal cancer, a particularly devastating cancer.”